compound 3f [Festa et al., 2019]   Click here for help

GtoPdb Ligand ID: 10187

Compound class: Synthetic organic
Comment: Compound 3f is a non-steroidal, selective farnesoid X receptor (FXR) antagonist with a novel 3,5-disubstituted oxadiazole chemotype [1]. It is proposed as a promising lead that is suitable to further the investigation of the therapeutic value of FXR antagonists in the treatment of cholestasis and related metabolic disorders. Antagonist binding to FXR renders the receptor unable to recruit the coactivators it requires for transcriptional activation, and results instead in transcriptional silencing of FXR target genes. 3f exhibits no agonistic activity toward FXR.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 50.95
Molecular weight 279.14
XLogP 3.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N1CCC(CC1)c1onc(n1)c1ccc2c(c1)cccc2
Isomeric SMILES N1CCC(CC1)c1onc(n1)c1ccc2c(c1)cccc2
InChI InChI=1S/C17H17N3O/c1-2-4-14-11-15(6-5-12(14)3-1)16-19-17(21-20-16)13-7-9-18-10-8-13/h1-6,11,13,18H,7-10H2
InChI Key PPCNFLPYHQIYHP-UHFFFAOYSA-N
Bioactivity Comments
3f reduces recruitment of the co-activator SRC-1 to FXR in a cell-free system with an efficacy of 80% [1].
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Farnesoid X receptor Hs Antagonist Antagonist 6.2 pIC50 - 1
pIC50 6.2 (IC50 5.8x10-7 M) [1]
Description: Cellular potency (HepG2 cells) measured as antagonism of CDCA-induced FXR activation in a transactivation reporter assay.